Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Figures corrected NBB
Corrected annual account filed for 2023.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
AstriVax Therapeutics from Leuven, company number BE0787990881, closed financial year 2025 with a result of € -7.7 million after tax. Compared with financial year 2024, the result moved from € -8.2 million to € -7.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 21, 2026.
€ 10.7 million
▼ 42% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -7.7 million
▲ 7 % less loss than in 2024
Profit after tax over the fiscal year.
€ 3.2 million
▼ 68% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -5.1 million.
People and assets in 2025
17.1
▼ 2.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.6 million
▲ 1% vs 2024
€ 154,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 43,558
▼ 31% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 33,000
▼ 25% vs 2024
€ 11,000 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 686,849
▼ 51% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 38 days on average.
€ 258,352
▼ 34% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € -5,278,906 | - | - | |
| Profit after taxes | € -6,742,248 | € -8,198,285 | € -7,657,682 | ▲ € 540,602 |
| Equity | € 14,546,227 | € 18,347,942 | € 10,690,260 | ▼ 42% |
| Total debts | € 5,490,927 | € 3,172,872 | € 1,838,750 | ▼ 42% |
| Cash | € 3,409,537 | € 10,130,138 | € 3,191,847 | ▼ 68% |
| Retained profit | € -6,742,248 | € -8,198,285 | € -5,080,196 | ▲ € 3.1 million |
| Bank debt | € 0 | € 44,000 | € 33,000 | ▼ 25% |
| Balance sheet total | € 20,037,153 | € 21,520,814 | € 12,529,009 | ▼ 42% |
| Employees (FTE) | 12.5 | 19.5 | 17.1 | ▼ 2.4 |
Key figures of AstriVax Therapeutics, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AstriVax Therapeutics?
What happened at AstriVax Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Dieter Karl Weinand stepped down as director. NBB
- Jeanne Bolger stepped down as director. NBB
- Participatiemaatschappij Vlaanderen NV stepped down as director. NBB
- OMX EUROPE VENTURE FUND FPCI BO stepped down as director. NBB
- Shelley Margetson stepped down as director. NBB
- Bart Geers stepped down as director. NBB
- Hanxelle BV stepped down as director. NBB
- Evan Castiglia stepped down as director. NBB
In short
From € 6.7 million loss in 2023 to € 7.7 million loss in 2025.
Pays suppliers within 38 days on average.
A new publication or filing at AstriVax Therapeutics? We notify you, reason included.
Follow AstriVax TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Fund+, Flanders Future Techfund, V-Bio Fund 2 comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
AstriVax TherapeuticsBehind AstriVax Therapeutics is Halina Novak. The shares are held by Fund+ (17.2%), Flanders Future Techfund (14.3%) and V-Bio Fund 2 (14.3%).
Directors
According to the 2025 annual accounts
Halina Novak
Director
since 2024
Participatiemaatschappij Vlaanderen NV
Director · represented by Bart De Taeye
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE, BIOTECH FONDS VLAANDEREN, MAISON DE LA RADIO FLAGEY, HERTECANT FLANGES, Site-Ontwikkeling Vlaanderen, SUSTAINABLE ENERGY VENTURES +136 more
since 2022 · until 2028
Dieter Karl Weinand
Director
since 2025 · until 2031
OMX EUROPE VENTURE FUND FPCI BO
Director · represented by Eva Van Overmeire
Also active at: Microbial Resource Management Technologies
since 2022 · until 2028
Shelley Margetson
Director
since 2022 · until 2028
since 2022 · until 2028
Director · represented by Hanne Callewaert
since 2022 · until 2028
Jeanne Bolger
Director
since 2022 · until 2028
Evan Castiglia
Director
since 2023 · until 2028
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3 box 4
3001 Leuven
Gaston Geenslaan 3
3001 Leuven
Active since 4 July 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics same network
€ -528,262 gross margin · 2025
AUGUSTINE THERAPEUTICS same network
€ -1.7 million gross margin · 2025
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0787.990.881
- VAT number
- BE 0787.990.881
- Registered office
- Gaston Geenslaan 3 bus 4, 3001 Leuven
- Names & denominations
- AstriVax Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 4 July 2022
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied